The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
复制标题
DOI：
10.1016/j.cllc.2020.07.016
复制
发表时间：
2021-01
影响因子：
3.6
通讯作者：
Villaflor VM
中科院分区：
文献类型：
--
作者：
Oh MS;Guzner A;Wainwright DA;Mohindra NA;Chae YK;Behdad A;Villaflor VM
β受体阻滞剂与抗肿瘤作用有关，可能是通过减少肾上腺素能介导的应激反应。临床前研究还表明，β-受体阻滞剂可能会增强癌症免疫治疗的疗效。我们调查了同时使用β受体阻滞剂和免疫检查点抑制剂的肺癌患者，假设β受体阻滞剂将对临床结果产生积极影响。我们回顾了2014年1月至2018年8月期间在西北大学接受免疫检查点抑制剂治疗的109名非小细胞肺癌(NSCLC)患者的健康记录。对109例接受免疫检查点抑制剂治疗的非小细胞肺癌患者的总生存期(OS)和无进展生存期(PFS)进行Kaplan-Meier分析和LOG-RANK检验，用Cox比例风险模型进行单因素回归分析，其中28例同时服用β受体阻滞剂。β受体阻滞剂的使用与PFS的增加有关，危险比(HR)为0.58，95%可信区间(CI)为0.36-0.93。服用β受体阻滞剂的患者的总生存率(OS)没有显著增加(HR为0.66，95%CI为0.38-1.17)。在回归模型中，β受体阻滞剂与非鳞状组织学、肿瘤PD-L1阳性和较低的治疗路线一样被认为是预测PFS的指标。我们的数据表明，在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中，β受体阻滞剂的使用可能与改善PFS有关。这是一项小型研究，这些发现应该在前瞻性临床研究中得到进一步验证。这项研究回顾了β受体阻滞剂对接受免疫治疗的肺癌患者的临床结果的影响。在这些患者中，使用β-受体阻滞剂与改善无进展生存率有关。这些发现与先前关于压力信号在抗癌免疫中的重要性的工作一致，应该在前瞻性研究中进一步探索。
Beta blockers have been associated with anti-tumorigenic effects, potentially by reducing adrenergic-mediated stress responses. Preclinical studies have additionally shown that beta blockade may enhance the efficacy of cancer immunotherapy. We investigated lung cancer patients who concomitantly used beta blockers and immune checkpoint inhibitors, with the hypothesis that beta blockade would positively impact clinical outcomes. We retrospectively reviewed the health records of 109 patients who were treated at Northwestern University between January 2014 through August 2018 with immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). Comparisons of overall survival (OS) and progression-free survival (PFS) were performed using Kaplan-Meier analysis with log-rank test, and a univariate regression analysis was performed with a Cox proportional hazards model Among 109 patients treated with immune checkpoint inhibitors for NSCLC, 28 of them were concomitantly prescribed beta blockers. Use of beta blockers was associated with increased PFS, with hazard ratio (HR) of 0.58 and 95% confidence interval (CI) of 0.36-0.93. There was not a significant increase in overall survival (OS) among patients who took beta blockers (HR 0.66, 95% CI 0.38-1.17). In a regression model, beta blockers were identified as predictive of PFS, as were non-squamous histology, tumor PD-L1 positivity, and lower line of treatment. Our data suggests beta blocker use may be associated with improved PFS among patients treated with immune checkpoint inhibitors for NSCLC. This was a small study and these findings should be further validated in prospective clinical studies. This study retrospectively assessed the effect of beta blockers on clinical outcomes in lung cancer patients who were treated with immunotherapy. Beta blocker use was associated with improved progression-free survival in these patients. These findings align with prior work regarding the importance of stress signaling in anti-cancer immunity and should be further explored in prospective studies.
登录
查看更多内容
影响因子：
4.2
作者：
Choy C;Raytis JL;Smith DD;Duenas M;Neman J;Jandial R;Lew MW
通讯作者：
Lew MW
影响因子：
17.1
作者：
Nilsson MB;Sun H;Diao L;Tong P;Liu D;Li L;Fan Y;Poteete A;Lim SO;Howells K;Haddad V;Gomez D;Tran H;Pena GA;Sequist LV;Yang JC;Wang J;Kim ES;Herbst R;Lee JJ;Hong WK;Wistuba I;Hung MC;Sood AK;Heymach JV
通讯作者：
Heymach JV
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
2.6
作者：
Ali, A.;Goffin, J. R.;Ellis, P. M.
通讯作者：
Ellis, P. M.
影响因子：
--
作者：
Christensen, Desire K.;Armaiz-Pena, Guillermo N.;Lutgendorf, Susan K.
通讯作者：
Lutgendorf, Susan K.